Syros Pharmaceuticals, Inc.
November 13, 2024 - by Joey Ramson
Shares of $SYRS, the biggest laggard in the Prism MarketView Pharmaceuticals index are down over 80% today after its trial for tamibarotene, failed in a late-stage study for a rare blood cancer.
